This is in reply to the Letter by Kahathuduwa et al. titled “Unaccounted for regression to the mean renders conclusion of article titled ‘Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin’ unsubstantiated”

Diabetes, Obesity and Metabolism, EarlyView.

Source: Diabetes, Obesity and Metabolism - June 6, 2018 Category: Endocrinology Authors: Motoshi Ouchi MD , Kenzo Oba MD , Hideki Suganami PhD , Akihiro Yoshida , Tomoe Fujita MD , Tatsuya Suzuki MD , Masahiro Yasutake MD , Kohei Kaku MD Source Type: research